Subcutaneous semaglutide: Additional Phase IIIa data

Additional data from the double-blind, international Phase IIIa SUSTAIN 1 trial in 388 treatment-naive Type II diabetics previously on diet and

Read the full 214 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE